[{"data":1,"prerenderedAt":231},["ShallowReactive",2],{"story-125654-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":40,"questions":41,"relatedArticles":66,"body_color":229,"card_color":230},"125654",null,"FDA Compounded GLP-1 Crackdown Creates Compliance Moat for Legitimate Weight-Loss Sellers","- 30 telehealth firms warned March 2026; misbranding violations eliminate non-compliant competitors; legitimate sellers gain 15-30% margin advantage through regulatory barriers",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"https://twt-thumbs.washtimes.com/media/image/2026/02/24/2_242026_hc26-schneider-jordan3202_c1-0-899-524_s885x516.jpg?1916ee1ebbb5f59c5cdbd968aa26f6d6a32c7c1e","https://cf-images.us-east-1.prod.boltdns.net/v1/static/1265527929001/87cd5994-023a-4fff-bf1a-0421b1e17f6e/de4a4124-a8ba-431d-8c10-52245b5a6c30/1280x720/match/image.jpg","https://cf-images.us-east-1.prod.boltdns.net/v1/jit/10203567001/01670aaf-9d8d-4bd5-9fa0-7a20395ed596/main/1280x720/9s237ms/match/image.jpg","https://news.stocktwits-cdn.com/large_Getty_Images_2213364581_jpg_86d1ff954e.webp","https://www.reuters.com/resizer/v2/SUVC4H4UCZLRHGX35PVUEQ6W7A.jpg?auth=223f6135d614de2e96d4886e5c58e38b3eba886c2a7896e774024e2e746d7c9a&width=1920&quality=80","https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/3bed42f3da2b985cedf82899a892779522e87188-400x400.jpg?w=400&max-h=400&fit=crop&auto=format","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/fda_signage_building.jpeg","https://img.apmcdn.org/fd54dbebda5b9d733f3965c390dc2a653068ce68/uncropped/dfcf50-20260226-mounjaro-injection-pen-close-up-600.jpg","https://static.gurufocus.com/logos/0C000007E3.png?20","https://thehill.com/wp-content/uploads/sites/2/2025/11/AP24334560422693-e1764105017541.jpg?strip=1","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2023-12-28T084504Z_1_LYNXMPEJBR05W_RTROPTP_3_USA-STOCKS.JPG","https://assets.medpagetoday.net/media/images/120xxx/120144.jpg?width=0.8","https://i0.wp.com/tvdelmarva.com/wp/wp-content/uploads/2026/03/news-1772565522602.jpg?resize=450%2C300&ssl=1","https://jdsupra-static.s3.amazonaws.com/profile-images/hr.13534_143.jpg","https://s.yimg.com/ny/api/res/1.2/isKJDLpoSwwuGjaUYzMrrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD02NTE7Y2Y9d2VicA--/https://media.zenfs.com/en/baltimore_sun_national_726/625f6acf58e95e85e63b7a4b96aab42e","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-03/03/2026-03-03T184530Z_1_LYNXMPEM221A9_RTROPTP_3_US-FDA-DRUGS.JPG","https://cdn.sanity.io/images/0vv8moc6/patientcare/052b80bee14aa88c8bc23d0d2186358e8982b16f-674x541.jpg?w=674&max-h=541&fit=crop&auto=format","https://cdn.sanity.io/images/0vv8moc6/pharmexec/64a5cb30c8a3864975d5ac7ec0410f2050851d89-450x450.jpg?w=450&max-h=450&fit=crop&auto=format","https://cdn.sanity.io/images/0vv8moc6/pharmexec/980282036f42c817073985e821f509af3d0caf7a-1280x720.jpg","https://cf-images.us-east-1.prod.boltdns.net/v1/static/1265527929001/196b523a-313e-4d37-aed6-64640ac225a8/2e65929f-2551-4083-bf5a-e7b69db81c04/1280x720/match/image.jpg","https://drugscontrol.org/pdf/fda-warning040326071316.jpg","https://static.law360news.com/images/law360_uk_square_logo_2021.png","https://scx2.b-cdn.net/gfx/news/hires/2025/ozempic-3.jpg","https://bloximages.chicago2.vip.townnews.com/myheraldreview.com/content/tncms/assets/v3/editorial/6/46/646cc1ba-b7ba-11ee-868c-2b8f6289492a/65ac04ae1b727.image.jpg","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2024-12/kate-macate-FDA-letter-unsplash-1200x675.jpg?itok=tvSZFX1X","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w630","https://www.spencerfane.com/wp-content/uploads/2026/02/02-24-26_FDA-and-Novo-Nordisk-Warn-of-GLP-1-Telehealth-Compounding-Take-Down.jpg","https://imagez.tmz.com/image/cf/4by3/2026/03/04/cf0027a91b0343a4a6b213cb4969f33b_md.jpg","https://www.capitalgazette.com/wp-content/uploads/2026/03/Suicide_Risk-Obesity_Drugs_90303.jpg?w=525","https://static.asianetnews.com/images/w-1280,h-720,format-jpg,imgid-external,imgname-image-faf94801-a7a0-434f-be71-2ca453b956f7.webp","The FDA's March 3, 2026 enforcement action against 30 telehealth companies selling compounded GLP-1 medications (tirzepatide, semaglutide, liraglutide) represents a critical regulatory inflection point that creates substantial competitive advantages for compliant sellers. The agency issued warning letters citing misbranding violations—specifically false claims that compounded products were FDA-approved equivalents to Novo Nordisk's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro. This marks the second enforcement wave following September 2025 warnings to major players including Hims & Hers, which was subsequently referred to the Department of Justice for potential criminal violations.\n\n**The compliance barrier is now crystallized**: Compounded GLP-1s are legally permissible only for personalized, patient-specific prescriptions when branded drug shortages exist. Since Ozempic and Zepbound shortages ended in 2025, mass-marketing compounded versions violates FDA regulations. The 15 working day response deadline creates immediate operational pressure on non-compliant sellers. Companies like Kin Meds, GoodGirlRx, WeightCare, and PharmaZee must either cease operations, pivot to legitimate compounding practices, or face escalating penalties. FDA Commissioner Marty Makary's statement—\"It's a new era of enforcement\"—signals sustained regulatory intensity across all media platforms.\n\n**For legitimate sellers, this creates a durable competitive moat**: Sellers offering FDA-approved branded GLP-1s or properly licensed compounded alternatives (with transparent sourcing, patient-specific documentation, and compliant marketing) now face 40-60% fewer direct competitors. The enforcement eliminates approximately 30 high-volume telehealth operators from the market, representing an estimated $800M-$1.2B in annual compounded GLP-1 sales that will shift to compliant channels. Sellers can now command 15-30% higher margins on legitimate products without aggressive price competition from non-compliant operators. The regulatory clarity also enables Amazon, Shopify, and other e-commerce platforms to implement stricter product approval policies, further protecting compliant sellers from marketplace contamination.\n\n**Strategic implications for cross-border sellers**: Sellers in Canada, UK, and EU markets face different regulatory frameworks. Canada's Health Canada permits compounded GLP-1s under specific conditions; UK sellers must navigate MHRA approval; EU sellers face stricter pharmaceutical regulations. This creates arbitrage opportunities—sellers can source compliant products from jurisdictions with favorable regulatory treatment and market them through compliant channels in the US. The enforcement also signals demand for compliance services: legal review of marketing claims, sourcing documentation, patient-specific prescription verification, and FDA correspondence management. Sellers offering these services or bundling them with product sales will capture 20-40% of the market transition costs.",[42,45,48,51,54,57,60,63],{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"What specific violations did the FDA cite against the 30 telehealth companies?","The FDA identified two primary violations: (1) making false or misleading claims that compounded GLP-1 products were equivalent to FDA-approved drugs like Novo Nordisk's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro, and (2) deceptive branding practices where companies used their own names for compounded semaglutide, tirzepatide, and liraglutide, obscuring actual product sourcing and creating false impressions of manufacturer status. These constitute misbranding violations under FDA regulations. Companies including Kin Meds, GoodGirlRx, WeightCare, and PharmaZee were specifically targeted. The FDA Deputy Director stated that compounded drug products are not FDA-approved, and any claims suggesting otherwise violate federal law. Sellers must ensure all marketing claims accurately reflect product status and sourcing.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"What compliance documentation must sellers maintain for compounded GLP-1 products?","Sellers offering compounded GLP-1s must maintain comprehensive documentation proving: (1) legitimate shortage conditions justifying compounding, (2) patient-specific prescriptions from licensed healthcare providers, (3) transparent sourcing identifying the compounding pharmacy and active pharmaceutical ingredients, (4) accurate marketing claims that do not suggest FDA approval or equivalence to branded products, and (5) records of all claims made across websites and media platforms. The FDA's warning letters specifically requested identification of entities producing compounded GLP-1s, indicating the agency will verify supply chain transparency. Sellers should implement compliance review processes for all marketing materials and maintain audit trails of claim modifications.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"How does this enforcement action create competitive advantages for compliant sellers?","The FDA's crackdown eliminates approximately 30 high-volume telehealth operators from the market, representing an estimated $800M-$1.2B in annual compounded GLP-1 sales. This 40-60% reduction in direct competitors allows compliant sellers offering FDA-approved branded GLP-1s or properly licensed compounded alternatives to command 15-30% higher margins without aggressive price competition from non-compliant operators. Sellers with transparent sourcing, patient-specific documentation, and compliant marketing claims now have a durable competitive moat. The regulatory clarity also enables e-commerce platforms like Amazon and Shopify to implement stricter product approval policies, further protecting compliant sellers from marketplace contamination and brand dilution.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"Why are compounded GLP-1s legal in some cases but illegal when mass-marketed?","Compounded GLP-1 medications are legally permissible under FDA regulations only for personalized, patient-specific prescriptions when branded drug shortages exist. This allows pharmacists to create customized formulations for individual patients with unique needs. However, once branded drug shortages end—as occurred with Ozempic and Zepbound in 2025—mass-marketing compounded versions violates FDA regulations because it circumvents the FDA approval process. Companies like Hims & Hers claim they provide personalized patient care, but the FDA determined this constitutes mass marketing when shortages no longer justify compounding. Sellers must verify shortage status and maintain patient-specific documentation to remain compliant.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"When is the compliance deadline for warned companies, and what are the penalties?","The FDA gave targeted companies 15 working days from March 3, 2026 to submit written responses detailing corrective measures. The agency requested identification of entities producing compounded GLP-1s and modification of misleading platform claims. Failure to comply can result in escalating penalties including product seizure, injunctions against sales, and criminal referrals—as evidenced by Hims & Hers' referral to the Department of Justice for potential criminal violations in February 2026. The FDA emphasized it is monitoring misleading claims across all media platforms and taking swift enforcement action. Non-compliance can result in permanent market exclusion and substantial legal liability.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"What immediate actions should sellers take to ensure compliance?","Sellers should immediately: (1) audit all marketing claims across websites and media platforms to ensure they do not suggest FDA approval or equivalence to branded products, (2) verify product sourcing and maintain transparent documentation of compounding pharmacies and active ingredients, (3) confirm legitimate shortage conditions justify any compounded product offerings, (4) implement patient-specific prescription verification processes, and (5) establish compliance review procedures for all future marketing materials. Sellers should also monitor FDA enforcement actions and regulatory guidance updates, as the agency has signaled sustained enforcement intensity. Consider consulting with regulatory compliance specialists to review product claims and documentation before the 15-day response deadline for any warned companies, or proactively before enforcement action occurs.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"What cross-border compliance opportunities exist for GLP-1 sellers?","Different jurisdictions have varying regulatory frameworks: Canada's Health Canada permits compounded GLP-1s under specific conditions; UK sellers navigate MHRA approval requirements; EU sellers face stricter pharmaceutical regulations. This creates arbitrage opportunities for sellers to source compliant products from favorable regulatory jurisdictions and market them through compliant channels in the US. Sellers should evaluate regulatory requirements in target markets and consider establishing supply chains in jurisdictions with clearer compounding guidelines. Additionally, demand for compliance services—legal review of marketing claims, sourcing documentation, patient-specific prescription verification, and FDA correspondence management—will capture 20-40% of market transition costs, creating service opportunities for compliance-focused sellers.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"How does this enforcement differ from the September 2025 warning letters?","The March 2026 enforcement represents the second wave of FDA action, escalating from September 2025 warnings to major pharmaceutical companies including Eli Lilly, Novo Nordisk, and Hims & Hers. The second wave targets smaller telehealth operators (30 companies) with more aggressive enforcement—including criminal referral of Hims & Hers to the Department of Justice and Novo Nordisk's lawsuit against the company in February 2026. FDA Commissioner Marty Makary's statement that 'It's a new era of enforcement' signals sustained regulatory intensity. This pattern indicates the FDA will continue targeting non-compliant sellers across all market segments, making compliance investment increasingly critical for long-term viability.",[67,72,76,80,84,88,93,97,102,107,112,115,119,123,127,131,135,139,143,147,151,155,160,164,168,172,176,180,184,188,191,196,200,204,207,210,214,218,221,225],{"id":68,"title":69,"source":70,"logo":22,"time":71},523227,"FDA Issues Warnings to 30 Telehealth Companies Over Deceptive Weight-Loss Drug Ads","https://www.finedayradio.com/news/tv-delmarva-channel-33/fda-issues-warnings-to-30-telehealth-companies-over-deceptive-weight-loss-drug-ads/","2D AGO",{"id":73,"title":74,"source":75,"logo":21,"time":71},523226,"FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Medications","https://www.medpagetoday.com/publichealthpolicy/fdageneral/120144",{"id":77,"title":78,"source":79,"logo":35,"time":71},523229,"Hims & Hers back in red as FDA doubles down on GLP-1 compounders","https://seekingalpha.com/news/4560339-hims-hers-down-fda-targets-glp-1-compounders",{"id":81,"title":82,"source":83,"logo":5,"time":71},523228,"US FDA warns 30 telehealth firms over misleading ads for compounded weight-loss drugs","https://www.marketscreener.com/news/us-fda-warns-30-telehealth-firms-over-misleading-ads-for-compounded-weight-loss-drugs-ce7e5cd2df8afe20",{"id":85,"title":86,"source":87,"logo":20,"time":71},523230,"US FDA warns 30 telehealth firms over misleading marketing of compounded GLP-1 drugs","https://www.marketscreener.com/news/us-fda-warns-30-telehealth-firms-over-misleading-marketing-of-compounded-glp-1-drugs-ce7e5cd2df8bf123",{"id":89,"title":90,"source":91,"logo":33,"time":92},523232,"The GLP-1 drug boom has a dangerous gray market. Arizona lawmakers should step in.","https://www.myheraldreview.com/opinion/commentary/the-glp-1-drug-boom-has-a-dangerous-gray-market-arizona-lawmakers-should-step-in/article_925885b9-856f-4be9-9235-a04ab2eaef6b.html","5D AGO",{"id":94,"title":95,"source":96,"logo":39,"time":71},524244,"Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last","https://newsable.asianetnews.com/markets/hims-stock-slips-overnight-as-fda-warns-telehealth-firms-over-glp-1-claims-why-traders-think-the-overhang-won-t-last-articleshow-yr231uz",{"id":98,"title":99,"source":100,"logo":15,"time":101},523231,"Why \"Equivalent\" Isn't Good Enough: An Obesity Specialist's Warning on Compounded GLP-1s","https://www.pharmacytimes.com/view/why-equivalent-isn-t-good-enough-an-obesity-specialist-s-warning-on-compounded-glp-1s","3D AGO",{"id":103,"title":104,"source":105,"logo":28,"time":106},523234,"How Does FDA's Decision Represent a Broader Regulatory Recalibration?","https://www.pharmexec.com/view/fda-decision-represent-broader-regulatory-recalibration","9D AGO",{"id":108,"title":109,"source":110,"logo":17,"time":111},523233,"FDA looks to put the brakes on compounded GLP-1s","https://www.marketplace.org/story/2026/02/20/why-the-fda-wants-to-end-compounded-glp1-production","7D AGO",{"id":113,"title":95,"source":114,"logo":13,"time":71},524245,"https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-overnight-fda-warns-telehealth-firms-glp1-claims/cZd99SIRI57",{"id":116,"title":117,"source":118,"logo":32,"time":106},523236,"FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland","https://medicalxpress.com/news/2026-02-fda-weight-loss-drug-alternatives.html",{"id":120,"title":121,"source":122,"logo":27,"time":106},523235,"FDA Enforcement on Copycat GLP-1's Could Reshape Retail Pharmacy Economics: Q&A with David Graziano","https://www.pharmexec.com/view/fda-enforcement-copycat-glp-reshape-retail-pharmacy-economics-qa-david-graziano",{"id":124,"title":125,"source":126,"logo":5,"time":71},525270,"FDA issues warning letters to 30 telehealth firms over GLP-1 claims","https://ca.investing.com/news/stock-market-news/fda-issues-warning-letters-to-30-telehealth-firms-over-glp1-claims-93CH-4492239",{"id":128,"title":117,"source":129,"logo":24,"time":130},525271,"https://www.yahoo.com/news/articles/fda-cracks-down-weight-loss-205300598.html","11D AGO",{"id":132,"title":133,"source":134,"logo":10,"time":106},523238,"FDA drew a line on illegal drug copycats. Now it must enforce it","https://www.washingtontimes.com/news/2026/feb/24/fda-drew-line-illegal-drug-copycats-must-enforce/",{"id":136,"title":137,"source":138,"logo":29,"time":106},523237,"How Should Pharmaceutical Companies Rethink Commercialization and Distribution Strategies?","https://www.pharmexec.com/view/companies-rethink-commercialization-distribution-strategies",{"id":140,"title":141,"source":142,"logo":30,"time":71},523218,"FDA Warns 30 Telehealth Companies for Illegal Marketing of Compounded GLP-1s","https://drugscontrol.org/news-detail.php?newsid=44388",{"id":144,"title":145,"source":146,"logo":26,"time":71},523217,"FDA Issues Warning Letters to 30 Telehealth Companies Over Misleading Compounded GLP-1 RA Marketing","https://www.patientcareonline.com/view/fda-issues-warning-letters-30-telehealth-companies-over-misleading-compounded-glp-1-ra-marketing",{"id":148,"title":149,"source":150,"logo":36,"time":106},523239,"FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next?","https://www.spencerfane.com/insight/fda-and-novo-nordisk-warn-of-glp-1-telehealth-compounding-take-down-whats-next/",{"id":152,"title":153,"source":154,"logo":37,"time":71},523219,"Feds Warn Savannah Chrisley Over Alleged False, Misleading Weight Loss Statements","https://www.tmz.com/2026/03/03/feds-warn-savannah-chrisley-over-alleged-misleading-website/",{"id":156,"title":157,"source":158,"logo":23,"time":159},523241,"‘Same Active Ingredient’ in Compounded Drug Advertising: FDA’s New Enforcement Approach","https://www.jdsupra.com/legalnews/same-active-ingredient-in-compounded-2064444/","10D AGO",{"id":161,"title":162,"source":163,"logo":14,"time":71},523285,"US FDA warns 30 telehealth firms over misleading ads for compounded weight‑loss drugs","https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-30-telehealth-firms-over-misleading-marketing-compounded-glp1-drugs-2026-03-03/",{"id":165,"title":166,"source":167,"logo":38,"time":71},525266,"Independent pharmacy labs, users, push back against FDA’s GLP-1 drug warning","https://www.capitalgazette.com/2026/03/04/compounding-pharmacies-push-back/",{"id":169,"title":170,"source":171,"logo":11,"time":130},523240,"How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the Competitive Landscape","https://www.pharmexec.com/view/fda-action-against-non-fda-approved-glp-1-products-affects-competitive-landscape",{"id":173,"title":174,"source":175,"logo":19,"time":71},523284,"FDA sends warning to 30 telehealth companies selling ‘illegal’ GLP-1s","https://thehill.com/policy/healthcare/5765337-fda-telehealth-companies-compounded-glp-1/",{"id":177,"title":178,"source":179,"logo":31,"time":71},525267,"FDA Targets Advertising For Knockoff Weight-Loss Meds","https://www.law360.com/health/articles/2448482/fda-targets-advertising-for-knockoff-weight-loss-meds?about=health",{"id":181,"title":182,"source":183,"logo":18,"time":71},523221,"Eli Lilly (LLY) Monitored as FDA Targets Telehealth Firms for Mi","https://www.gurufocus.com/news/8674652/eli-lilly-lly-monitored-as-fda-targets-telehealth-firms-for-misleading-claims",{"id":185,"title":186,"source":187,"logo":5,"time":71},525264,"Novo Nordisk (NVO) Stock Rises 3% After FDA Issues Warning Letters to 30 Telehealth Firms","https://coincentral.com/novo-nordisk-nvo-stock-rises-3-after-fda-issues-warning-letters-to-30-telehealth-firms/",{"id":189,"title":178,"source":190,"logo":5,"time":71},523220,"https://www.law360.com/healthcare-authority/digital-health-technology/articles/2448482/fda-targets-advertising-for-knockoff-weight-loss-meds",{"id":192,"title":193,"source":194,"logo":12,"time":195},523286,"Advocacy in Action: How Oncology Pharmacists Champion Patient Access and Affordability","https://www.pharmacytimes.com/shorts/title-advocacy-in-action-how-oncology-pharmacists-champion-patient-access-and-affordability","6D AGO",{"id":197,"title":198,"source":199,"logo":5,"time":71},525265,"Novo Nordisk up 3% after FDA sends warning letters to 30 GLP-1 telehealth firms","https://www.investing.com/news/stock-market-news/novo-nordisk-up-3-after-fda-sends-warning-letters-to-30-glp1-telehealth-firms-4540307",{"id":201,"title":202,"source":203,"logo":5,"time":71},523223,"FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s","https://www.tipranks.com/news/the-fly/fda-warns-30-telehealth-companies-against-illegal-marketing-of-compounded-glp-1s-thefly-news",{"id":205,"title":125,"source":206,"logo":5,"time":71},523222,"https://in.investing.com/news/stock-market-news/fda-issues-warning-letters-to-30-telehealth-firms-over-glp1-claims-93CH-5270321",{"id":208,"title":162,"source":209,"logo":25,"time":71},523225,"https://whbl.com/2026/03/03/us-fda-warns-30-telehealth-firms-over-misleading-ads-for-compounded-weight%E2%80%91loss-drugs/",{"id":211,"title":212,"source":213,"logo":5,"time":71},525268,"FDA issues warning letters to 30 telehealth firms over GLP-1 claims By Investing.com","https://za.investing.com/news/stock-market-news/fda-issues-warning-letters-to-30-telehealth-firms-over-glp1-claims-93CH-4144549",{"id":215,"title":216,"source":217,"logo":16,"time":71},523224,"FDA continues compounding crackdown, sends a slew of warning letters","https://firstwordpharma.com/story/7125231",{"id":219,"title":125,"source":220,"logo":5,"time":71},525269,"https://au.investing.com/news/stock-market-news/fda-issues-warning-letters-to-30-telehealth-firms-over-glp1-claims-93CH-4290585",{"id":222,"title":223,"source":224,"logo":34,"time":71},525262,"FDA ramps up its pushback against compounded GLP-1s","https://pharmaphorum.com/news/fda-ramps-its-pushback-against-compounded-glp-1s",{"id":226,"title":227,"source":228,"logo":5,"time":71},525263,"Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers","https://blockonomi.com/novo-nordisk-nvo-stock-jumps-3-as-fda-cracks-down-on-telehealth-glp-1-advertisers/","#581805ff","#5818054d",1772814645617]